A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Official Title

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Summary:

This is an open label, multi-centre, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy. Safety, efficacy and tolerability of BBI503 will be assessed for the duration of study treatment.

Trial Description

Primary Outcome:

  • Disease Control Rate (DCR)
Secondary Outcome:
  • Objective response rate (ORR)
  • Progression free survival (PFS)
  • Overall survival (OS)
  • Pharmacodynamics (biomarkers) of BBI503 when tumour biopsy is possible
  • Number of Patients with Adverse Events

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society